金吾财讯 | Aquestive Therapeutics(AQST)盘前股价拉升，暂报4.21美元，升幅42%。消息面上，公司于2026年1月30日收到了美国食品和药物管理局（FDA）发出的完整回应信（CRL），该信函针对其寻求批准用于治疗I型过敏反应（包括过敏性休克）的一款新药申请（NDA），该药品为Anaphylm（dibutepinephrine）舌下膜剂，适用于体重大于30公斤（约66磅）的患者。公司表示，该药品缺陷仅限于包装和管理。公司相信能够迅速解决缺陷，并预计最早在2026年第三季度重新提交。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.